SCHEMBL5135064

SCHEMBL5135064

CCCCn1c(CN(CCc2ccccc2)Cc2ccc(SC)cc2)cnc1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.41
TSHR P16473 2/20 0.39
BCHE P06276 4/20 0.36
QPCT Q16769 1/20 0.34
C5AR1 P21730 1/20 0.34
KDM4E B2RXH2 1/20 0.33
HSD17B10 Q99714 1/20 0.33
DRD2 P14416 1/20 0.33
OPRM1 P35372 1/20 0.33
DRD3 P35462 1/20 0.33
OPRD1 P41143 1/20 0.33
OPRK1 P41145 1/20 0.33
PDE4B Q07343 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136238 1.00 HSD11B1 (0.41) HSD11B1TSHRBCHEQPCTC5AR1
SCHEMBL5135214 0.93 TSHR (0.43) HSD11B1TSHRQPCTC5AR1KDM4E
SCHEMBL5075074 0.92 TSHR (0.46) HSD11B1TSHRBCHEDRD2OPRM1
SCHEMBL5136109 0.91 HSD11B1 (0.41) HSD11B1TSHRBCHEC5AR1KDM4E
SCHEMBL5072355 0.91 HSD11B1 (0.45) HSD11B1TSHRBCHEC5AR1DRD2
SCHEMBL5135667 0.90 HSD11B1 (0.44) HSD11B1TSHRBCHEC5AR1DRD2
SCHEMBL5134920 0.90 HSD11B1 (0.44) HSD11B1TSHRBCHEC5AR1DRD2
SCHEMBL5073933 0.88 HSD11B1 (0.43) HSD11B1TSHRBCHE
SCHEMBL5134787 0.86 BCHE (0.42) HSD11B1TSHRBCHE
SCHEMBL5135920 0.86 BCHE (0.44) HSD11B1TSHRBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed